Quanterix (QTRX) Net Income towards Common Stockholders (2017 - 2026)
Quanterix's (QTRX) quarterly Net Income towards Common Stockholders came in at -$17.5 million in Q1 2026, up 14.45% YoY from -$15.3 million in Q1 2025, and up 24.12% on a QoQ basis from -$23.1 million in Q4 2025.
Quanterix (QTRX) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
Quanterix (QTRX) has 10 years of Net Income towards Common Stockholders data on file, last reported at -$17.5 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 14.45% year-over-year to -$17.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$104.2 million (down 117.64% YoY) and the FY2025 annual result came in at -$107.2 million, down 178.09% from the prior year.
- Net Income towards Common Stockholders advanced to -$17.5 million in Q1 2026, from -$23.1 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$5.6 million in Q2 2023 to a low of -$36.6 million in Q3 2022.
- A 5-year average of -$17.1 million and a median of -$17.5 million in 2026 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders jumped 81.63% — and 2025, when it tumbled 306.29%.
- Tracing QTRX's Net Income towards Common Stockholders over 5 years: stood at -$18.2 million in 2022, then soared by 51.57% to -$8.8 million in 2023, then plunged by 31.94% to -$11.6 million in 2024, then plunged by 98.8% to -$23.1 million in 2025, then rose by 24.12% to -$17.5 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$17.5 million (Q1 2026), -$23.1 million (Q4 2025), and -$33.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn | 907.00 Mn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 621.86 Mn |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Quanterix | 148.63 Mn | 55.10 Mn | 12.67 Mn | -48.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -48.93 Mn |
| Mar 31, 2026 | -17.54 Mn |
| Dec 31, 2025 | -23.12 Mn |
| Sep 30, 2025 | -33.52 Mn |
| Jun 30, 2025 | -30.01 Mn |
| Mar 31, 2025 | -20.50 Mn |
| Dec 31, 2024 | -11.63 Mn |
| Sep 30, 2024 | -8.35 Mn |
| Jun 30, 2024 | -7.39 Mn |
| Mar 31, 2024 | -11.16 Mn |
| Dec 31, 2023 | -8.81 Mn |
| Sep 30, 2023 | -6.72 Mn |
| Jun 30, 2023 | -5.55 Mn |
| Mar 31, 2023 | -7.27 Mn |
| Dec 31, 2022 | -18.20 Mn |
| Sep 30, 2022 | -36.55 Mn |
| Jun 30, 2022 | -26.91 Mn |
| Mar 31, 2022 | -17.92 Mn |
| Dec 31, 2021 | -17.89 Mn |
| Sep 30, 2021 | -15.66 Mn |